Ropivacaine, compared to bupivacaine, tends to have a shorter and less intense motor blockade but similar sensory blockade characteristics in terms of depth, duration, and onset. It also presents a reduced risk of arrhythmias and cardiodepressive effects at recommended doses, although these benefits diminish at higher concentrations. The maximum dose of ropivacaine for regional anesthesia is 3 mg/kg, with or without epinephrine; epinephrine does not raise ropivacaine's ceiling.
For interscalene blockade, using 0.2% ropivacaine rather than 0.1% results in a longer duration of the block and decreased opioid requirements post-surgery, despite similar pain scores and no significant differences in forced vital capacity (FVC), forced expiratory volume (FEV1), length of stay, or total opioid consumption in the post-anesthesia care unit (PACU). Before performing significant regional blocks, it is crucial to ensure that an IV is functional. Accidental subarachnoid injection during epidural administration could lead to persistent anesthesia, paresthesia, or lower extremity paralysis with potential slow or no recovery.
IV regional anesthesia, such as the Bier block, is not recommended due to risks of high plasma concentrations and associated cardiac arrest following tourniquet release. Notably, ropivacaine, unlike the other amides, has intrinsic vasoconstrictor activity at clinical concentrations (cocaine is the only other local anesthetic that constricts vessels); however, adding epinephrine only improves the quality of analgesia without affecting the duration, systemic absorption, or onset time.
In obstetric applications, ropivacaine requires lower doses. High plasma levels may cause uterine vasoconstriction and reduce uterine blood flow, leading to fetal bradycardia or death. This risk is particularly evident in paracervical blocks, hence ropivacaine is discouraged for this use. When dosed equivalently to bupivacaine, ropivacaine does not prolong labor, influence delivery mode, or result in adverse neonatal outcomes. Labor epidural analgesia uses dilute solutions; the concentrated 0.75-1% solutions are reserved for surgical epidural anesthesia.
Epidural or intrathecal administration of ropivacaine can lead to hypotension and bradycardia, managed by fluid hydration, vasopressors, and left uterine displacement for pregnant patients. Muscarinic antagonists may also be used for bradycardia treatment. Naropin should be discarded 24 hours after opening and used with caution in renal failure due to increased plasma concentrations and prolonged action.
In summary, ropivacaine provides effective local and regional anesthesia with a safety profile that addresses the cardiotoxicity seen with bupivacaine, making it a valuable option in clinical anesthesia, particularly considering its metabolic and elimination pathways through hepatic and renal processes respectively.
